Abstract Number: 1768 • ACR Convergence 2023
The Dynamics of the Gut Microbiome in Rheumatoid Arthritis Susceptibility: A Cross-Sectional and Longitudinal Observational Study
Background/Purpose: Multiple compositional shifts of gut microbiota have been identified within the rheumatoid arthritis (RA) disease continuum, encompassing both established RA and at-risk individuals (including…Abstract Number: 0571 • ACR Convergence 2023
A Polygenic Risk Score for Systemic Lupus Erythematosus (SLE) Discriminates Between Patients with Lupus and Individuals Without Lupus and a Positive Antinuclear Antibody Test
Background/Purpose: A positive ANA (ANA-POS) test is present in almost all patients with SLE and is also frequently present in other autoimmune (AI) diseases and…Abstract Number: 1950 • ACR Convergence 2023
Thromboembolic Risk Associated with Intravenous Immune Globulin Use in Patients with Idiopathic Inflammatory Myopathy: A Large Database Study
Background/Purpose: Intravenous immune globulin (IVIG) recently received regulatory approval for the treatment of dermatomyositis, one of the idiopathic inflammatory myopathies (IIM). The pivotal randomized trial…Abstract Number: 0620 • ACR Convergence 2023
Physical and Mental Health in Early Systemic Sclerosis: Baseline Results for Patient-Reported Outcomes Measurement Information System-29 from the Collaborative National Quality and Efficacy Registry
Background/Purpose: Patient-Reported Outcomes Measurement Information System-29 version 2.0 (PROMIS-29v2) is a patient-centered questionnaire used to assess health-related quality of life (HRQoL). PROMIS-29v2 has shown validity…Abstract Number: 1996 • ACR Convergence 2023
Variation in Dual-energy X-ray Absorptiometry Reporting: A National Survey of Veterans Health Administration Clinics
Background/Purpose: Dual-energy x-ray absorptiometry (DXA) is an important tool to identify Veterans with osteoporosis, assess fracture risk, and monitor treatment response. Variability in DXA acquisition,…Abstract Number: 0633 • ACR Convergence 2023
Prediction of Progressive Fibrosing Interstitial Lung Disease in Systemic Sclerosis Patients: Insight from the CRDC Cohort Study
Background/Purpose: Systemic sclerosis (SSc) patients can develop progressive fibrosing interstitial lung disease (PF-ILD), linked to a poor outcome. This study aims to establish a reliable…Abstract Number: 2132 • ACR Convergence 2023
Systematic Screening for Multimorbidities Leads to an Increased Use of Comorbidity-preventing Medications and Lower Hospitalization Rates
Background/Purpose: Systematic screening for multimorbidities has been carried out since 2014 at Montpellier University Hospital in patients with chronic inflammatory rheumatism (IRD). The aim of…Abstract Number: 107 • 2023 Pediatric Rheumatology Symposium
Validation of Serious Adverse Event Reporting in a Multicenter Registry
Background/Purpose: Children with rheumatic disease frequently require management with immune suppressing medications. The benefits of these interventions often outweigh the risks, however serious adverse events…Abstract Number: 0993 • ACR Convergence 2022
SARS-CoV-2 Vaccine Side Effects and Infections in SLE
Background/Purpose: SLE patients are an especially vulnerable population in the face of the COVID pandemic due to their dysregulated endogenous immune system, further downregulated by…Abstract Number: 1984 • ACR Convergence 2022
Malignancies Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a National Study: RELATION Study
Background/Purpose: Patients with IMID, and notably patients with rheumatoid arthritis RA, are at increased risk of cancer compared with the general population. It is hence…Abstract Number: 1047 • ACR Convergence 2022
A Novel Prediction Tool for Progression of Systemic Sclerosis-Interstitial Lung Disease Despite Treatment with Immunosuppression
Background/Purpose: Systemic sclerosis-interstitial lung disease (SSc-ILD) is the leading cause of SSc-related death. While some patients respond favorably to treatment with immunosuppression, a subset of…Abstract Number: 2268 • ACR Convergence 2022
Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Background/Purpose: Long-term anticoagulation is the standard of care for antiphospholipid syndrome (APS) patients with macrovascular thrombosis. However, in daily practice, long-term anticoagulation may not be…Abstract Number: 1049 • ACR Convergence 2022
Risk Stratification of Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension in EUSTAR Using the Current and New Proposed Criteria
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major clinical challenge in systemic sclerosis (SSc). A new definition for precapillary PH is proposed. Risk stratification is…Abstract Number: 1249 • ACR Convergence 2022
Short-term Variations in Subchondral Tibial Bone Texture of Conventional X-Rays Predicts Knee Osteoarthritis Progression
Background/Purpose: Early detection and assessment of Knee Osteoarthritis (KOA) prognostic factors are crucial for developing management and treatments that aim at prevention of irreversible damage…Abstract Number: 0084 • ACR Convergence 2022
Facilitators and Barriers of Vaccine Uptake in Patients with Chronic Inflammatory Rheumatic Disease: A Scoping Review
Background/Purpose: Patients with chronic inflammatory rheumatic diseases (CIRD) remain underrepresented in receiving vaccinations despite being disproportionately affected by infectious complications. The aim of our study…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 8
- Next Page »